Colorectal Cancer Metastatic Clinical Trial
— SIMULTOfficial title:
Simultaneous Resection of Colorectal Cancer and Synchronous Liver Metastases: What Determines the Risk of Unfavorable Outcomes? A Retrospective International Multicenter Study
NCT number | NCT05475041 |
Other study ID # | NP5467 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 30, 2022 |
Est. completion date | July 22, 2022 |
Verified date | July 2022 |
Source | Fondazione Poliambulanza Istituto Ospedaliero |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The use of a simultaneous resection in patients with synchronous colorectal liver metastases has increased over the past decades. However, it remains unclear when a simultaneous resection is beneficial and when it should be avoided. The objective of this retrospective study is therefore to compare the outcomes of a simultaneous resection for synchronous colorectal liver metastases in different settings, and to assess which factors are independently associated with unfavorable outcomes.
Status | Completed |
Enrollment | 766 |
Est. completion date | July 22, 2022 |
Est. primary completion date | July 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Elective minimally invasive or open simultaneous resection of colorectal cancer and synchronous colorectal liver metastases Exclusion Criteria: - (Partially) robotic-assisted or thoracoscopic procedures - First stage of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) - Patients that underwent major concurrent procedures |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Poliambulanza Istituto Ospedaliero | Brescia | Lombardy |
Lead Sponsor | Collaborator |
---|---|
Fondazione Poliambulanza Istituto Ospedaliero | Amsterdam UMC location University of Amsterdam, Antoine Béclère Hospital Paris, Clinica Universidad de Navarra Pamplona, Groeninge Hospital Kortrijk, Hospital Doctor Josep Trueta de Girona, IRCCS Azienda Ospedaliero-Universitaria di Bologna, IRCCS San Raffaele Hospital Milan, Moscow Clinical Research Centre, Oslo University Hospital and Institute of Medicine, Riuniti Hospital Polytechnic University of Marche Ancona, The Queen Elizabeth Hospital, Umberto I Mauriziano Hospital Turin, Università Cattolica del Sacro Cuore-IRCCS Rome, Universita di Verona, University Hospital Padua, University Hospital Southampton NHS Foundation Trust |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major complications | Severe complications (Clavien-Dindo grade 3a or higher) related to the surgical procedure | 30 days postoperatively | |
Secondary | Overall complications | Overall complications related to the surgical procedure | 30 days postoperatively | |
Secondary | Length of hospital stay | The length of hospital stay for the surgical procedure | 30 days postoperatively | |
Secondary | R0 resection margin | Proportion of patients in whom a microscopically radical resection of both the primary colorectal carcinoma and the liver metastases was performed. | 30 days postoperatively | |
Secondary | Intraoperative blood loss | Intraoperative blood loss in milliliters | During the surgical procedure | |
Secondary | Operative time | Operative time in minutes | During the surgical procedure | |
Secondary | Conversion to open surgery | Intra-operative conversion to an open or hand-assisted procedure in the minimally invasive group | During the surgical procedure | |
Secondary | Mortality | Postoperative mortality | 90 days postoperatively | |
Secondary | Red blood cell transfusion | Intraoperative red blood cell transfusion | During the surgical procedure | |
Secondary | Intraoperative incidents | Intraoperative unfavourable incidents | During the surgical procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03941080 -
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Completed |
NCT03647839 -
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Terminated |
NCT02316496 -
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
|
Phase 2 | |
Completed |
NCT03251612 -
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02380443 -
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02149784 -
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT01959061 -
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
|
Phase 4 | |
Terminated |
NCT01668680 -
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05068531 -
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
|
||
Not yet recruiting |
NCT04525807 -
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
|
||
Completed |
NCT04482608 -
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
|
||
Recruiting |
NCT03193710 -
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
|
N/A | |
Recruiting |
NCT04854213 -
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 | |
Completed |
NCT03144804 -
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01910610 -
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05759728 -
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |